Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
Department of Biochemistry and Molecular Biology, Biomedical Center, Vatnsmyrarvegur 16, 101, Reykjavik, Iceland.
Oncogene. 2019 Nov;38(45):7106-7112. doi: 10.1038/s41388-019-0936-x. Epub 2019 Aug 13.
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
人类肿瘤显示出蛋白质同工型的改变模式,这些改变模式可能与转化细胞中观察到的信使 RNA 可变剪接失调有关。虽然在某些情况下已经描述了核心剪接体成分及其相关因子的体细胞突变,但几乎不知道扭曲的表观遗传模式对异常剪接的贡献。在此,我们表明,剪接 RNA 结合蛋白 CELF2 是人类癌症中启动子过度甲基化相关转录沉默的靶标。我们专注于乳腺癌的情况,还证明 CELF2 的恢复具有生长抑制作用,其表观遗传缺失会诱导异常的下游可变剪接模式,影响乳腺癌生物学中的关键基因,如自噬因子 ULK1 和凋亡蛋白 CARD10。此外,在临床环境中存在 CELF2 高甲基化与携带这种表观遗传病变的乳腺癌患者的总生存期更短有关。